Gli eventi si terranno in modalità ibrida, sia online che in presenza presso l’Auditorium all’Ospedale Regionale di Bellinzona e Valli – Bellinzona
- 24 gennaio
Optimizing the designs of early clinical trials in oncology
Christina Yap, UK,
Professor of Clinical Trials Biostatistics, The Institute of Cancer Research, UK
- 14 febbraio
Senolytic immune cells therapies for prostate cancer
Andrea Alimonti, CH,
Head of molecolar oncology at the Institute of Oncology Research (IOR-CH),
Full Professor of Oncology USI, ETH, CH
Full professor of Pharmacology UNiPD, IT
- 27 marzo
The changing landscape of relapsed and refractory diffuse large B-cell lymphoma
Andrew Davies, UK
Professor of Haematological Oncology and Honorary Consultant, University of Southampton, UK
Chair UK National Lymphoma Research Group
Director Southampton Experimental Cancer Medicines Centre
- 17 aprile
Advances in DDR targeting: what can we expect in the next years
Timothy A Yap, USA
Professor, Department of Investigational Cancer Therapeutics (Phase I Program)
Vice President, Head of Clinical Development, Therapeutics Discovery Division
Associate Director of Translational Research, Khalifa Institute for Personalized Cancer Therapy
The University of Texas MD Anderson Cancer Center
- 15 maggio
Systematic reviews in a nutshell
Giorgio Treglia, CH
Medical education and Research Area and Imaging Institute of Southern Switzerland, EOC, Bellinzona
Professor, Faculty of Biomedical sciences, USI, Lugano
Faculty of Biology and Medicine, UNIL, Lausanne
- 19 giugno
Management of antibody-drug conjugates toxicities
Joseph Gligorov, FR
Professor of Medical Oncology Sorbonne Université
Medical Director of DMU ORPHé AP-HP Sorbonne Université
- 18 settembre
ctDNA and MRD in solid tumors: current state and future directions
Umberto Malapelle, IT
Chair of Predictive Molecular Pathology Laboratory, Department of Public Health
University Federico II of Naples, Italy
- 23 ottobre
New KRAS inhibitors beyond G12C
Fabrice Barlesi, FR
General Director of Gustave Roussy
Professor of Medicine at the Paris Saclay University, France
- 20 novembre
Update on cellular therapies for solid tumours
Andrew Furness, UK
Consultant Medical Oncologist, Solid Tumour Cellular Therapy Lead, The Royal Marsden NHS Foundation Trust
Team Leader and Clinical Lead, Centre for Translational Immunotherapy, The Institute of Cancer Research
